BioCentury
ARTICLE | Top Story

Peptide passes Phase III trial

June 5, 2000 7:00 AM UTC

Peptide (LSE:PTE) said Arilvax, its live attenuated yellow fever vaccine, met its Phase III primary end point by demonstrating equivalence to a control vaccine. The trial was conducted in 1,440 healthy adults, half on Arilvax, half on YF-Vax, the control vaccine. A sample of 310 patients were selected from each group and assessed for production of yellow fever neutralizing antibodies. Both vaccines were highly immunogenic with seroprotection rates of 99 percent. No serious adverse events were reported. PTE is compiling the data from the trial to submit a BLA to the FDA later this year. ...